| Business Summary | | 3-Dimensional
Pharmaceuticals,
Inc.
is
a
drug
discovery
company
that
discovers
and
develops
its
own
drug
candidates,
which
it
generally
licenses
at
the
pre-clinical
or
early
clinical
stage.
The
Company
is
also
using
its
technologies
to
assist
collaborators
in
discovering
drug
candidates.
To
facilitate
this
process,
the
Company
has
developed
an
integrated
set
of
proprietary
technologies,
called
DiscoverWorks,
which
accelerate
and
improve
the
drug
discovery
process
and
capitalize
on
the
opportunities
presented
by
new
targets
for
drugs
being
revealed
from
the
sequencing
of
the
human
genome.
The
Company's
technologies
also
facilitate
drug
discovery
for
well-characterized
disease
targets
that
have
proven
difficult
using
traditional
methods.
DiscoverWorks
technologies
can
efficiently
assimilate
and
process
vast
quantities
of
data
produced
from
the
combination
of
combinatorial
chemistry
and
high-throughput
screening,
and
can
be
rapidly
and
efficiently
scaled
to
meet
increasing
demand. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | DDDP
is
a
drug
discovery
company
that
has
developed
an
integrated
set
of
technologies
for
the
cost-effective
discovery
of
small
molecule
pharmaceuticals.
For
the
six
months
ended
6/30/01,
revenues
rose
from
$3.6
million
to
$12.4
million.
Net
loss
applicable
to
Common
fell
28%
to
$4.7
million.
Revenues
reflect
new
and
continuing
collaborations
with
Bristol-Myers,
Centocor
and
Schering
AG.
Lower
loss
reflects
an
increase
in
interest
income
and
a
decrease
in
interest
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| James Cavanaugh, Ph.D., 64 Chairman | -- | -- | David U'Prichard, Ph.D., 52 CEO,
Director | $675K | $486K | F. Raymond Salemme, Ph.D., 56 Pres,
CSO, Director | 395K | 336K | Wendy Nagy, 58 Sr.
VP, Gen. Counsel | -- | -- | Roger Bone, Ph.D., 43 Sr.
VP of R&D | 232K | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|